Adage Capital Partners
SMMT icon

Adage Capital Partners’s Summit Therapeutics SMMT Stock Holding History

Adage Capital Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29M Buy
+1,989,591
New +$35.3M 0.04% 397
2025
Q2 		– Sell
-538,000
Closed -$10.4M – 942
2025
Q1 		$10.4M Buy
+538,000
New +$10.8M 0.02% 577

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Adage Capital Partners's SMMT Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 1,989,591 shares worth $29M. The stake represents 0.04% of the portfolio and ranks #397 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in SMMT as recently as Q1 2025.

Adage Capital Partners first reported a position in SMMT in Q1 2025 and has held it in 2 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Adage Capital Partners held 1,989,591 shares of Summit Therapeutics worth $29M as of Q2 2026.
  • Summit Therapeutics was a new Adage Capital Partners position in Q2 2026.
  • Summit Therapeutics made up 0.04% of Adage Capital Partners's portfolio in Q2 2026, its #397 holding.
  • Adage Capital Partners first reported a position in Summit Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.